Six members of the UH community participated in the inaugural Innov8 Hub's Innovators to Founders Cohort. Photo via UH.edu

A new accelerator at the University of Houston recently wrapped its first program for a cohort of five early-stage startups.

Known as the Innov8 Hub's Innovators to Founders Cohort, the accelerator is a founder-driven program in partnership with the UH Technology Bridge, the Innovation Center, and the Texas Gulf Coast Small Business Development Center (SBDC). Innov8 is designed to aid six to eight aspiring entrepreneurs bring their concepts to market and assist them in applying for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants.

Founders recently showcased their work before potential partners and investors at the hub's first-ever Startup Pitch Day following the conclusion of the 12-week program.

“The goal of the programs is for the founders to launch new ventures and develop business plans they can use to raise money and attract C-suite level employees to join their team,” Tanu Chatterji, associate director of startup development at Tech Bridge and co-founder of Innov8 Hub, said in a statement. “These programs aren’t classroom-teacher driven so the founders have to commit to engage and spend the time necessary to reap the benefits.”

The Innovators to Founders Cohort runs for three months each semester. Cohort members will devote three hours each week to the program. Photo via UH.edu

The inaugural cohort included:

Shoujun Xu, UForce Biotechnology: Xu is a chemistry professor at UH and has developed a new technique of super-resolution force spectroscopy, or SURFS, and plans to launch his company, UForce Biotechnology, in the future. He aims to use the SURFS technique to advance drug screening. His pitch at the Startup Pitch Day was named the best of the night, and Xu went home with $7,500 in legal services and one year of coworking space free of charge.

Easy Anyama, ODX Health: Anyama is a fourth-year student in the UH College of Optometry. His company, ODX Health, aims to improve "data harmonization, interoperability and integration in eyecare to reduce inefficiencies and enhance health outcomes," according to UH.

Jeremy Tee and Easy Anyama, Ringit: Anyama joined fellow fourth-year student in the UH College of Optometry Jeremy Tee in a second pitch, Ringit. The startup aims to provide a low-cost medication management solution for the visually impaired. It is developing an adaptive labeling system that helps the visually impaired identify their medication and dosages independently via intuitive, "touch-based features," according to UH.

Jan Beetge, AltiSora: Beetge has developed "Botox for wood." The product is made from high- sustainability raw materials that are non-hazardous and non-toxic. Potential applications include waterproofing of electronic equipment or electrical cables or connections in cables, such as cables used in marine applications, according to the company's website.

Jason Shi, Smart Planter Project: Shi is developing a "high-tech planter, a device that autonomously takes care of your plants and keeps them healthy while you’re gone," according to UH. He aims to soon test the product with customers.

The Innovators to Founders Cohort runs for three months each semester. Cohort members will devote three hours each week to the program.

The Innov8 Hub also offers an SBIR/STTR Support Cohort and a WKI Program for Student Entrepreneurial Support Cohort.

Last year, UH also named eight graduate students to its first-ever UH-Chevron Energy Graduate Fellows cohort.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.